Abstract
The multidrug resistance (MDR) of tumor cells significantly reduces the efficiency of traditional anticancer therapy. Tumor MDR is complex and involves several mechanisms such as decreased drug uptake, increased drug efflux, enhanced drug exocytosis, increased drug detoxification and inactivation by drugmetabolizing enzymes, altered drug targets due to genetic and epigenetic modifications, altered DNA repair, and impaired apoptotic pathways. Implementation of nanoparticles can markedly improve drug delivery through increased stability in the plasma, prolonged half-life, enhanced specificity of transfer, and advanced drug accumulation and retention in the tumor cells. So far, many various types of nanocarriers have been used for the delivery of anticancer agents. These carriers greatly increase anti-tumor effects of cytotoxic agents since drug-carrying nanoparticles are able to reverse MDR. The promising integrative approach in cancer nanotherapy assumes the development of multifunctional delivery systems simultaneously transmitting various agents such as drugs, genes, imaging agents, and targeting ligands in order to enhance anti-tumor toxicity and nanoparticle tracking.
Keywords: Multidrug resistance, cancer chemotherapy, nanoparticles, drug delivery, cytotoxicity, tumor.
Current Pharmaceutical Design
Title:Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Volume: 23 Issue: 22
Author(s): Dimitry A. Chistiakov, Veronika A. Myasoedova, Alexander N. Orekhov and Yuri V. Bobryshev*
Affiliation:
- Institute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow 121609,Russian Federation
Keywords: Multidrug resistance, cancer chemotherapy, nanoparticles, drug delivery, cytotoxicity, tumor.
Abstract: The multidrug resistance (MDR) of tumor cells significantly reduces the efficiency of traditional anticancer therapy. Tumor MDR is complex and involves several mechanisms such as decreased drug uptake, increased drug efflux, enhanced drug exocytosis, increased drug detoxification and inactivation by drugmetabolizing enzymes, altered drug targets due to genetic and epigenetic modifications, altered DNA repair, and impaired apoptotic pathways. Implementation of nanoparticles can markedly improve drug delivery through increased stability in the plasma, prolonged half-life, enhanced specificity of transfer, and advanced drug accumulation and retention in the tumor cells. So far, many various types of nanocarriers have been used for the delivery of anticancer agents. These carriers greatly increase anti-tumor effects of cytotoxic agents since drug-carrying nanoparticles are able to reverse MDR. The promising integrative approach in cancer nanotherapy assumes the development of multifunctional delivery systems simultaneously transmitting various agents such as drugs, genes, imaging agents, and targeting ligands in order to enhance anti-tumor toxicity and nanoparticle tracking.
Export Options
About this article
Cite this article as:
Chistiakov A. Dimitry, Myasoedova A. Veronika , Orekhov N. Alexander and Bobryshev V. Yuri *, Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives, Current Pharmaceutical Design 2017; 23 (22) . https://dx.doi.org/10.2174/1381612823666170407123941
DOI https://dx.doi.org/10.2174/1381612823666170407123941 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry The 18 kDa Translocator Protein (TSPO): A New Perspective in Mitochondrial Biology
Current Molecular Medicine The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Biodiversity and Chemodiversity: Future Perspectives in Bioprospecting
Current Drug Targets Network Systems Underlying Traditional Chinese Medicine Syndrome and Herb Formula
Current Bioinformatics Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews MicroRNAs and Chronic Inflammation Contribution to Gastrointestinal Integrity
Current Medicinal Chemistry Editorial: (Thematic Issue: Effect of Epi-drugs on Epigenetic Modifications Induced by Environmental Pollutants: Implications for the Pathophysiology of Cancer and Endocrine/metabolic Diseases)
Current Genomics Food-derived Bioactive Peptides - Opportunities for Designing Future Foods
Current Pharmaceutical Design Review on Fundamentals, Preparations and Applications of Imprinted Polymers
Current Organic Chemistry Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine An Exceptional Case of Atrial Fibrillation Arrhythmia Induced by Etoposide
Current Drug Safety Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Recent Progress in FKBP Ligand Development
Current Molecular Pharmacology β2-AR-HIF-1α: A Novel Regulatory Axis for Stress-Induced Pancreatic Tumor Growth and Angiogenesis
Current Molecular Medicine